[1] |
韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志,2013,18(4):330-334.
|
[2] |
韩苏军. 中国前列腺癌发病及死亡现状和流行趋势分析[D]. 北京:北京协和医学院,2015.
|
[3] |
朱耀,唐钵,戴波,等. 前列腺健康指数在中国男性前列腺癌诊断中的应用研究[J]. 中华外科杂志,2017,55(10):734-737.
|
[4] |
NA R,YE D,QI J,et al.Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL:results from a multicenter study in China[J]. Prostate,2017,77(11):1221-1229.
|
[5] |
马兰,张倩,张俊华,等. %p2PSA和phi联合检测在前列腺癌中的诊断价值[J]. 医药前沿,2016,6(20):108-109.
|
[6] |
PEYROMAURE M,FULLA Y,DEBRÉ B,et al.Pro PSA :a "pro cancer" form of PSA?[J]. Med Hypotheses,2005,64(1):92-95.
|
[7] |
MIKOLAJCZYK S D,MARKER K M,MILLAR L S,et al.A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer[J]. Cancer Res,2001,61(18):6958-6963.
|
[8] |
巫志宇,罗杰,吴斌,等. 血清前列腺特异性抗原同源异构体p2PSA的体外稳定性评估[J]. 免疫学杂志,2018,34(4):338-342.
|
[9] |
VUKOVIC I,DJORDJEVIC D,BOJANIC N,et al.Predictive value of [-2]propsa(p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0 ng/mL PSA range[J]. Int Braz J Urol,2017,43(1):48-56.
|
[10] |
TAN L G,TAN Y K,TAI B C,et al.Prospective validation of %p2PSA and the prostate health index,in prostate cancer detection in initial prostate biopsies of Asian men,with total PSA 4-10 ng ml-1[J]. Asian J Androl,2017,19(3):286-290.
|
[11] |
NA R,YE D,LIU F,et al.Performance of serum prostate-specific antigen isoform [-2]proPSA(p2PSA) and the prostate health index(PHI) in a Chinese hospital-based biopsy population[J]. Prostate,2015,74(15):1569-1575.
|
[12] |
WANG W,WANG M,WANG L,et al.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer:a meta-analysis[J]. Sci Rep,2014,4:5012.
|
[13] |
吴义启,刘修恒. 前列腺健康指数对前列腺癌的诊断价值[J]. 中华实验外科杂志,2015,32(5):1190-1192.
|
[14] |
闫存玲,李志艳,何群,等. 血清前列腺特异性抗原同源异构体2在前列腺癌诊断中的应用价值[J]. 中华检验医学杂志,2015,38(12):813-817.
|
[15] |
谭思嘉,许露伟,徐郑,等. PHI/PCA3在前列腺癌早期诊断中的应用价值探讨[J]. 中华医学杂志,2016,96(2):100-103.
|